Tenet Healthcare (NYSE: THC) has recently received a number of price target changes and ratings updates:
- 8/23/2026 – Tenet Healthcare was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 8/20/2026 – Tenet Healthcare was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
- 8/15/2026 – Tenet Healthcare was downgraded by Wall Street Zen from “strong-buy” to “buy”.
- 8/14/2026 – Tenet Healthcare had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $285.00 price target on the stock.
- 8/11/2026 – Tenet Healthcare was upgraded by Zacks Research from “hold” to “strong-buy”.
- 8/10/2026 – Tenet Healthcare was given a new $290.00 price target by Mizuho.
- 8/3/2026 – Tenet Healthcare had its price target raised by Wells Fargo & Company from $231.00 to $281.00. They now have an “overweight” rating on the stock.
- 8/3/2026 – Tenet Healthcare was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 7/28/2026 – Tenet Healthcare had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $305.00 price target on the stock.
- 7/28/2026 – Tenet Healthcare had its price target raised by Truist Financial Corporation from $270.00 to $290.00. They now have a “buy” rating on the stock.
- 7/28/2026 – Tenet Healthcare had its price target raised by Guggenheim from $242.00 to $283.00. They now have a “buy” rating on the stock.
- 7/28/2026 – Tenet Healthcare had its price target raised by Robert W. Baird from $210.00 to $280.00. They now have a “neutral” rating on the stock.
- 7/27/2026 – Tenet Healthcare had its “overweight” rating reaffirmed by Stephens. They now have a $285.00 price target on the stock.
- 7/27/2026 – Tenet Healthcare had its price target raised by UBS Group AG from $288.00 to $308.00. They now have a “buy” rating on the stock.
- 7/27/2026 – Tenet Healthcare was given a new $308.00 price target by Piper Sandler.
- 7/27/2026 – Tenet Healthcare had its price target raised by Morgan Stanley from $254.00 to $274.00. They now have an “overweight” rating on the stock.
- 7/27/2026 – Tenet Healthcare was given a new $270.00 price target by Raymond James Financial, Inc..
- 7/27/2026 – Tenet Healthcare had its “overweight” rating reaffirmed by Cantor Fitzgerald.
- 7/27/2026 – Tenet Healthcare had its price target raised by TD Cowen from $233.00 to $263.00. They now have a “buy” rating on the stock.
- 7/27/2026 – Tenet Healthcare had its price target raised by Royal Bank Of Canada from $236.00 to $283.00. They now have an “outperform” rating on the stock.
- 7/26/2026 – Tenet Healthcare was upgraded by Wall Street Zen from “hold” to “buy”.
- 7/24/2026 – Tenet Healthcare had its price target raised by UBS Group AG from $288.00 to $308.00. They now have a “buy” rating on the stock.
- 7/24/2026 – Tenet Healthcare had its price target raised by Barclays PLC from $240.00 to $271.00. They now have an “overweight” rating on the stock.
- 7/20/2026 – Tenet Healthcare had its price target lowered by Guggenheim from $252.00 to $242.00. They now have a “buy” rating on the stock.
- 7/18/2026 – Tenet Healthcare was downgraded by Wall Street Zen from “buy” to “hold”.
- 7/13/2026 – Tenet Healthcare had its price target raised by Wells Fargo & Company from $213.00 to $231.00. They now have an “overweight” rating on the stock.
- 7/8/2026 – Tenet Healthcare had its price target raised by Barclays PLC from $238.00 to $240.00. They now have an “overweight” rating on the stock.
Insider Activity
In other news, CEO Saumya Sutaria sold 50,000 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $278.71, for a total transaction of $13,935,500.00. Following the completion of the transaction, the chief executive officer directly owned 483,564 shares in the company, valued at approximately $134,774,122.44. This represents a 9.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Tammy Romo sold 2,500 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $260.83, for a total transaction of $652,075.00. Following the completion of the sale, the director owned 28,284 shares in the company, valued at $7,377,315.72. This represents a 8.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 108,037 shares of company stock valued at $28,965,972 in the last three months. 0.97% of the stock is currently owned by insiders.
In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.
Featured Stories
- Five stocks we like better than Tenet Healthcare
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Tenet Healthcare Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenet Healthcare Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
